Skip to main content

Table 1 Approved indications for PARPi by FDA & NMPA (in order of approval time)

From: The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing

Drug Approved Time Application Indication Clinical Trials
Olaparib 2014.12 (FDA) Late-line monotherapy Adult patients with advanced recurrent HGSOCs with germline BRCA mutations, who have received three or more prior lines of chemotherapy Study 42
Rucaparib 2016.12 (FDA) Late-line monotherapy Adult patients with advanced recurrent EOCs with germline BRCA mutations, who have received two or more prior lines of chemotherapy Study 10 & ARIEL2
Niraparib 2017.3 (FDA) Maintenance therapy Adult patients with recurrent EOCs, who had either a complete or a partial response to platinum-based chemotherapy NOVA
Olaparib 2017.8 (FDA) Maintenance therapy Adult patients with recurrent EOCs, who had either a complete or a partial response to platinum-based chemotherapy Study 19 & SOLO-2
Rucaparib 2018.4 (FDA) Maintenance therapy ARIEL3
Olaparib 2018.8 (NMPA) Maintenance therapy Study 19 & SOLO-2
Olaparib 2018.12 (FDA) Maintenance therapy Newly diagnosed adult EOC patients with BRCA mutations, who had either a complete or a partial response to first-line platinum-based chemotherapy (frontline maintenance therapy) SOLO-1
Niraparib 2019.10 (FDA) Late-line monotherapy Recurrent adult EOC after three or more prior lines of chemotherapy: who are BRCA mutated or HRD-positive and platinum sensitive QUADRA
Olaparib 2019.12 (NMPA) Maintenance therapy Newly diagnosed adult EOC patients with BRCA mutations, who had either a complete or a partial response to first-line platinum-based chemotherapy (frontline maintenance therapy) SOLO-1
Niraparib 2019.12 (NMPA) Maintenance therapy Adult patients with recurrent EOCs, who had either a complete or a partial response to platinum-based chemotherapy NOVA